Cyclo Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Cyclo Therapeutics Stock Summary

Cyclo Therapeutics competes with Lifecore Biomedical, Alpha Teknova, Petros Pharmaceuticals, Phibro Animal, and Intracellular. Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida. Cyclo Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.

Cyclo Therapeutics Key Financial Ratios

Cyclo Therapeutics Key Balance Sheet Accounts

Cyclo Therapeutics Key Cash Accounts

Cyclo Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cyclo Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclo Therapeutics competition to find correlations between indicators driving Cyclo Therapeutics's intrinsic value. More Info.Cyclo Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Cyclo Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclo Therapeutics' earnings, one of the primary drivers of an investment's value.

Cyclo Therapeutics Systematic Risk

Today, most investors in Cyclo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclo Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cyclo Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Cyclo Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cyclo Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cyclo Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Cyclo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cyclo Therapeutics's daily price indicators and compare them against related drivers.

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.